PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processes to Enhance Efficiency and Improve Cell Quality
TOKYO & TORONTO--(BUSINESS WIRE)--Feb 10, 2025--
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell (*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate 'LiCellGrow TM(*2), PHC's cell expansion system under development, with CCRM's deep knowledge of regenerative medicine and biomanufacturing to establish new culture processes to improve cell culture efficiency and quality for CGTs.
This press release features multimedia. View the full release here:
*For research purposes only. Anticipated visual image of LiCellGrow. All features subject to change. (Graphic: Business Wire)
Primary T-cells are used in process development and manufacturing for CGTs, such as in CAR-T cell therapy. (*3) However, primary T-cells derived directly from patients often exhibit significant variability in growth rates and quality, making it challenging for researchers to ensure stable cell counts and maintain quality throughout the culture process. To address these challenges and improve the quality of cell-based therapeutics, better cell culture processes are needed.
Chikara Takauo, Director of PHC and Head of the Biomedical Division that leads the company's Life Science business, commented: 'We are delighted to begin this joint research and development initiative with CCRM, a leader with 14 years of experience in the commercialization of regenerative medicine and CGT. By combining the technologies and expertise of both of our organizations, we aim to advance the manufacturing processes for cell-based therapeutics and cell culture technologies, contributing to the early practical application of CGT.'
PHC has developed proprietary In-Line monitoring technology to track key indicators of cell metabolism in real-time, which can help researchers address issues like cell quality and reproducibility, and establish optimal cell culture methods. This technology enables precise, continuous measurement of glucose uptake and lactate production during cell culture, providing a more precise understanding of changes in cell metabolism over time than is possible to observe using traditional sampling methods. In 2024, PHC launched the live-cell metabolic analyzer 'LiCellMo TM(*4) " incorporating this technology in the United States, Canada, Europe and some Asian markets including Japan, China, Singapore and Taiwan.
Building on this technology, the company is also developing 'LiCellGrow,' a cell expansion system designed to exchange media automatically based on the metabolic state of the cells and to maintain the culture environment in an optimal state. PHC aims to further expand its product lineup to seamlessly support research, process development, and commercial manufacturing of cell-based therapeutics.
'We are excited to collaborate with PHC to unlock new possibilities in cell culture,' explained Michael May, President and CEO of CCRM. 'Technology development partnerships, like this one, are key to advancing the industry and making CGT more cost effective, and therefore more accessible to patients around the world.'
The joint research with CCRM will allow PHC to analyze culture conditions using 'LiCellGrow' to establish optimal culture processes for primary T-cells. The collaboration will seek to accelerate LiCellGrow's development, contributing to improved cell quality, enhanced manufacturing efficiency, and cost reduction in the production of cell-based therapeutics.
(*1) Primary T cells, or autologous T cells, refer to T cells that are directly isolated from the body. T cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and may help fight cancer.
(*3) CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.
About the Biomedical Division of PHC Corporation
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, diagnostics and life sciences. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO 2 incubators and ultra-low temperature freezers.
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, diagnostics and life sciences. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO 2 incubators and ultra-low temperature freezers.
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group's consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com/global
About CCRM and OmniaBio
CCRM is a global, public-private partnership headquartered in Canada. It has received funding from the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors, and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a commercial-stage CDMO for manufacturing cell and gene therapies. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.
.
CONTACT: Contact for media inquiries:
Investor Relations & Corporate Communications Department
PHC Holdings Corporation
TEL: +81-3-6778-5311
E-mail: [email protected] for product and service:
Marketing Department, Biomedical Division PHC Corporation
E-mail: [email protected] for CCRM:
Stacey Johnson
1-647-309-1830
[email protected]
KEYWORD: JAPAN NORTH AMERICA CANADA ASIA PACIFIC
INDUSTRY KEYWORD: STEM CELLS BIOTECHNOLOGY TECHNOLOGY HEALTH ONCOLOGY MEDICAL DEVICES RESEARCH INFECTIOUS DISEASES GENETICS SCIENCE HARDWARE
SOURCE: PHC Corporation
Copyright Business Wire 2025.
PUB: 02/10/2025 12:00 AM/DISC: 02/10/2025 12:00 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Dollar steady as traders await details from US-China talks
By Ankur Banerjee SINGAPORE (Reuters) -The U.S. dollar was steady on Tuesday in tight trading as Washington and Beijing remained locked in trade talks that left investors on edge and hesitant in placing major bets while looking ahead to U.S. inflation report later in the week. Top economic officials from the world's two largest economies sought to defuse a bitter dispute that has widened from tariffs to restrictions over rare earths, with trade talks extending to a second day in London. The talks come after U.S. President Donald Trump and Chinese President Xi Jinping spoke by phone last week and at a crucial time for both economies, which are showing signs of strain from Trump's cascade of tariff orders since January. The lack of firm details from the talks despite positive notes from some officials and Trump meant the currency markets were frigid in Asian hours as traders held their position, reluctant to make major moves. The U.S. dollar was little changed against the yen at 144.57 in early trading. The euro last fetched $1.1425 and sterling was 0.1% firmer at $1.3563. "The extension of talks and some positive soundbites from the U.S. officials could offer short-term relief, markets are unlikely to buy into this optimism without real structural progress," said Charu Chanana, chief investment strategist at Saxo. Washington and Beijing are trying to revive a temporary truce struck in Geneva that had briefly lowered trade tensions and calmed markets. "Unlike the Geneva talks, where tariff relief provided easy wins, the London talks are now tackling thornier issues like chip export controls, rare earths, and student visas," said Chanana. "These are long-term, strategic matters—not easily resolved over a few days. That makes it harder to deliver a positive surprise." The Australian dollar, often seen as a proxy for risk sentiment, was flat at $0.652, while the New Zealand dollar was a touch firmer at $0.6058, staying close to the seven-month peak it touched last week. [AUD/] The dollar index, which measures the U.S. currency against six other units, was steady at 98.986, not far from the six-week low it touched last week. The index is down 8.7% this year as investors flee U.S. assets worried about the impact of tariffs and trade tensions on its economy and growth. Investor focus this week will be on the consumer price index report for May, due on Wednesday. The report could give insight into the tariff impact at a time investors are wary of any flare-ups in inflation. The CPI report will be one of the last key pieces of data before the Federal Reserve's June 17-18 meeting, with the U.S. central bank widely expected to hold rates steady. Fed officials have signalled that they are in no rush to cut interest rates and signs of economic resilience will likely cement their stance, but traders are pricing in nearly two 25-basis point cuts by the end of the year.
Yahoo
2 hours ago
- Yahoo
Asian Currencies Consolidate Amid U.S.-China Trade Talks
Asian currencies consolidated against the dollar in early trade amid U.S.-China trade talks in London.
Yahoo
2 hours ago
- Yahoo
Asian Undervalued Small Caps With Insider Buying For June 2025
As the Asian markets navigate a complex landscape of economic indicators and geopolitical tensions, small-cap stocks continue to capture investor attention with their potential for growth amid broader market fluctuations. In this environment, identifying promising small-cap opportunities often involves looking at factors such as insider buying trends and valuation metrics, which can provide insights into the confidence levels of those closest to these companies. Name PE PS Discount to Fair Value Value Rating Security Bank 4.4x 1.0x 37.20% ★★★★★★ Credit Corp Group 8.6x 2.0x 38.69% ★★★★★★ East West Banking 3.1x 0.7x 33.79% ★★★★★☆ Lion Rock Group 5.0x 0.4x 49.84% ★★★★☆☆ Dicker Data 18.6x 0.6x -14.39% ★★★★☆☆ Atturra 28.1x 1.2x 33.01% ★★★★☆☆ Sing Investments & Finance 7.4x 3.8x 38.01% ★★★★☆☆ Integral Diagnostics 152.5x 1.8x 35.74% ★★★☆☆☆ Eureka Group Holdings 18.5x 5.7x 24.03% ★★★☆☆☆ AInnovation Technology Group NA 2.3x 48.08% ★★★☆☆☆ Click here to see the full list of 64 stocks from our Undervalued Asian Small Caps With Insider Buying screener. Here's a peek at a few of the choices from the screener. Simply Wall St Value Rating: ★★★★☆☆ Overview: Asia United Bank is a Philippine-based commercial bank that provides a range of financial services, including loans, deposits, and investment products, with a market capitalization of ₱31.59 billion. Operations: Asia United Bank generates revenue primarily through its financial services operations, with a significant portion of its income derived from interest and fees. Over recent periods, the net income margin has shown an upward trend, reaching 54.61% by the end of 2024. The company's cost structure is dominated by operating expenses, including general and administrative costs and sales & marketing expenses. PE: 4.7x Asia United Bank, a smaller player in the financial sector, exhibits potential for value appreciation. Recent insider confidence is evident with Manuel Gomez purchasing 15,090 shares valued at PHP 890,310 in March 2025. The bank's Q1 2025 earnings showed net income rising to PHP 3.14 billion from PHP 2.34 billion year-on-year, indicating solid growth despite a high non-performing loan ratio of 2%. A recent board meeting discussed dividend declarations, suggesting shareholder returns remain a priority. Take a closer look at Asia United Bank's potential here in our valuation report. Assess Asia United Bank's past performance with our detailed historical performance reports. Simply Wall St Value Rating: ★★★★★☆ Overview: SSY Group is a company primarily engaged in the production and distribution of intravenous infusion solutions and medical materials, with a market capitalization of HK$5.85 billion. Operations: The company generates revenue primarily from its Intravenous Infusion Solution and Others segment, which significantly outweighs the Medical Materials segment. Over recent periods, the net income margin has shown fluctuations, with a notable increase to 20.40% as of December 2023. Operating expenses have consistently been a substantial portion of costs, driven largely by sales and marketing expenses. PE: 8.3x SSY Group, a smaller company in Asia's pharmaceutical sector, is capturing attention with its strategic moves and market position. Recently, insider confidence was demonstrated when an insider acquired 1.4 million shares for HK$4.72 million between March and June 2025. The company's focus on innovative drug approvals from China's NMPA enhances its growth prospects, while the commencement of share repurchases on June 2, 2025, could potentially increase net asset value and earnings per share. Despite relying on external borrowing for funding, SSY Group's earnings are projected to grow by nearly 10% annually. Unlock comprehensive insights into our analysis of SSY Group stock in this valuation report. Understand SSY Group's track record by examining our Past report. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Ho Bee Land is a real estate company engaged in property investment and development, with a market cap of approximately SGD 2.50 billion. Operations: The company's revenue is primarily derived from property investment and development, with significant contributions from both sectors. Over recent periods, the gross profit margin has shown a downward trend, decreasing to 57.41% by the end of 2024. Operating expenses are consistently managed around $34.38 million SGD in recent quarters, while non-operating expenses have fluctuated significantly, impacting net income outcomes. PE: 11.5x Ho Bee Land, a smaller player in the Asian market, has caught attention due to insider confidence. Executive Chairman Thian Poh Chua recently acquired 143,500 shares valued at S$248,972, indicating faith in the company's prospects. Despite earnings declining by 45.8% annually over five years and reliance on riskier external borrowing for funding, their recent dividend increase to 4 cents per share suggests a commitment to shareholder returns. Leadership changes may also signal strategic shifts ahead. Navigate through the intricacies of Ho Bee Land with our comprehensive valuation report here. Learn about Ho Bee Land's historical performance. Investigate our full lineup of 64 Undervalued Asian Small Caps With Insider Buying right here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PSE:AUB SEHK:2005 and SGX:H13. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
